#52026XC02325EU summary of marketing authorisation decisions for medicinal products, March 2026
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice lists EU decisions on medicinal product marketing authorisations taken in March 2026. It shows which products received new approvals, which existing authorisations were changed, and which products were withdrawn, so pharma companies, distributors, regulators, and healthcare supply teams can track portfolio status and update filings, labeling, supply, and compliance records. The main practical effect is administrative but important: several human medicines and veterinary products were approved, many existing authorisations were updated, and a few products were withdrawn. Companies named in the notice should check the specific entry for their product to confirm what changed and whether any follow-up action is needed with regulators or internal commercial teams.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- The EU granted new marketing authorisations for several human medicines and one veterinary product in March 2026.
- Many existing product authorisations were modified, which may require updates to labeling, product information, registrations, and internal compliance files.
- A small number of authorisations were withdrawn, meaning affected products should be checked for supply, marketing, and regulatory follow-up.
Obligations
What this law requires
MA holders listed under the March 2026 EU decisions must check the specific entry for their medicinal product and update internal regulatory, labeling, supply, and commercial records to reflect the new authorization, modification, or withdrawal status shown in the notice.
Holders of newly issued marketing authorisations must ensure their product is tracked as EU-authorized from the decision and notification dates stated in the notice and complete any internal launch, filing, and compliance actions linked to the new authorization.
Holders of marketing authorisations that were modified must implement the approved change in the Community Register entry and align product dossier, labeling, and distribution materials with the modified authorization.
Holders of marketing authorisations that were withdrawn must stop relying on the withdrawn EU authorisation and update compliance, portfolio, and supply records to reflect that the authorisation is no longer active.
Companies responsible for products with a changed status should verify the Community Register entry number and the decision/notification dates in the notice before taking any downstream regulatory action.